Provider record
The $149 rate on this page is not open-ended. The $149 rate covers 1.5 mg and 4 mg. The 4 mg price rises to $199 after this date. It stops applying on 2026-08-31, in 28 days.
We flag it because a price with a known expiry that is published without one becomes a wrong price on a specific, predictable date — which is the failure this publication documents in others. Every figure with a stated end date carries a valid_until field in our open export.
Embody: What We Hold, and What We Have Asked
We hold 1 price record for Embody. All are provider-reported rather than captured by us. Embody has answered none of the four disclosure questions we publish, so most of…
We hold 1 price record for Embody. All are provider-reported rather than captured by us. Embody has answered none of the four disclosure questions we publish, so most of the fields that decide a recommendation are blank on this page.
Why is this a record rather than a review?
Our provider reviews run to about 2,500 words because we hold enough on those companies to write that much without padding. For Embody we do not. Writing the same length from one uncaptured figure would produce something that reads authoritative and tells you nothing.
So this page publishes exactly what we hold, marks every gap, and states what we have asked for. It becomes a review when there is something to review.
Every record we hold
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Embody | compounded | compounded injectable | — | — | — | — | not captured | third_party | — |
What we have asked, and what is unanswered
| Question | Worth | Their answer | Status |
|---|---|---|---|
| Pharmacy traceability and quality disclosures | 15 pts | — | Not answered No public price |
| Clinical oversight and care continuity | 20 pts | — | Not answered No public price |
| State access and operational reliability | 10 pts | — | Not answered No public price |
| Cancellation, billing and support transparency | 10 pts | — | Not answered No public price |
| What is actually in the vial | 10 pts | — | Not answered No public price |
A dash means no figure held. How we grade evidence.
What is missing from the record, and why does that matter?
The blank cells above are not omissions. Until Embody names its fulfilling pharmacy and registration class, a reader cannot check that pharmacy against a state board or against FDA warning letters, and cannot tell whether the FDA's proposed 503B bulks exclusion affects their supply. Until it publishes an all-in price at a maintenance dose, the figure above describes the start of treatment rather than the cost of it.
Both are things Embody can change in an afternoon, and we publish the answer either way — see the disclosure register.
Frequently asked questions
Is Embody legitimate?
We have not assessed that. We hold price records and no answers to our disclosure questions, which is not enough to make a judgement in either direction.
How much does Embody cost?
We hold no obtainable figure, and it is provider-reported rather than captured by us. We do not know what it becomes at a maintenance dose.
Which pharmacy does Embody use?
They have not told us. No provider in our dataset has answered that question.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- GLP-1 Telehealth vs Local Weight-Loss ClinicComparisons
- GLP-1 Semaglutide Rx ToolTools
- GLP-1 Data API DocumentationData
Related coverage
- Eden Tirzepatide Review
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Provider and Study Source Ledger
- ED Medication Online: Generic Prices, Compounded Claims and What Actually Differs
- Editorial Standards
- Evidence and Citation Policy
- FDA Warning Letters to GLP-1 Telehealth: The Record, and How to Check Any Provider
- The First Twelve Weeks on a GLP-1: What the Trials Actually Show
GLP-1 Semaglutide Rx. “Embody: What We Hold, and What We Have Asked.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/providers/embody/
Quote the capture date beside a figure, not the date you read this page. Why.
| Route | Monthly | Twelve months | Evidence |
|---|---|---|---|
| Covered brand plus savings card | $25 | $300 | Provider-reported |
| Medicare GLP-1 Bridge | $50 | $600 | Reported |
| Approved oral GLP-1 | $149 | $1,788 | Captured at source |
| Compounded tirzepatide, flat, 12-month | $186 | $2,232 | Captured at source |
| Brand Zepbound, LillyDirect vials | $299–$449 | $4,788 | Captured at source |
| Brand Zepbound, retail pens | ~$1,060 | ~$12,720 | Third-party claim |
Prices re-confirmed at source on 2026-08-03. The compounded row has no trial of its own; every efficacy figure on this site was collected on the approved product. Full ladder and evidence grades: the ranking.